

**Blackhawk
Growth Corp.**

CSE:BLR

Strategic Acquisition of Hardenbrook

Investor Presentation 2024



Justin Hanka

CEO



Anoosh Manzoori

Non-Executive Director &
Chairman



Anthony Haberfield

Non-Executive Director





John Dinan

CFO

Our Team

Blackhawk has an experienced team of investment professionals with extensive experience in capital raising, M&A, and public listings.





Hardenbrook

World Leading Research & Innovation

Hardenbrook identifies, invests in and commercializes scientific and technical innovation developed at leading Universities. It secures cutting edge technologies and then launches new companies with quality management teams and capital for scale and expansion into **North America**.



Multiple Spin Outs Per Year

Hardenbrook is at the forefront of innovation and translates world class science into businesses. It has a growing portfolio of spinouts and a strong pipeline of opportunities. **Each spinout is on a pathway to IPO or M&A.**

Backed By Science and Patents

Hardenbrook "invest with impact" to found and scale transformational science backed companies in sectors such as AI & Computational Science, Life Sciences & Health Tech, Digital Health, Clean Technologies, and new emerging technologies.

Hardenbrook's mission is to accelerate and enhance the commercialization of groundbreaking science and technology innovations from tier-one Universities from Australia and New Zealand.

John A. Hardenbrook was one of the founding members that started the New York Stock Exchange on May 17, 1792.


Hardenbrook creates attractive returns for its stakeholders by creating spinouts from Australia and New Zealand and launching them in North America for commercialization.



Scalable Business Model

With each new spinout we create equity and opportunity to generate cash flow from the sale of our shares. We also generate returns from loans and convertible notes provided to our spinouts.

Hardenbrook is a co-founder of each spinout.





Blackhawk Growth Corp.

Blackhawk is an investment issuer listed on the Canadian Securities Exchange.

The Company has a history of investing in innovative and emerging companies in healthcare, food technology, and biopharma.

Together, we have the power to be one of the largest referrers to the Canadian Securities Exchange

Growing Portfolio

Growing portfolio of innovative companies progressing towards M&A and IPO.

Spinout companies with quality management, experienced board, defendable & innovative intellectual property, highly scalable products that can be sold globally, a clear business model and identifiable distribution pathway. We back companies that can change the world, solve problems for large groups of people and make the world a better place.

On Market Trend

Focus on IP rich opportunities in AI & Computational Science, Life Sciences & Health Tech, Digital Health, Clean Technologies, and new emerging technologies.

Hardenbrook owns units in two funds

Hardenbrook has an investment in two funds. The funds have investments in listed and unlisted companies in Australia and Canada and provides cash flow to Hardenbrook as the assets are sold.


SPARC AI

CSE: SPAI

<https://www.sparcai.co>



Determining the location of a drone is easy, but determining the location of a distant object that is 100 miles away is a challenge. Using patented technology, SPARC AI can determine the location of any distant object without the use of the internet, GPS or satellite. Using proprietary and patented algorithms, SPARC AI can be installed on any camera device or sensor.



MindBio Therapeutics

- MindBio Therapeutics established as a spinout from a tier 1 University.
- MindBio signed an exclusive agreement with the University to undertake Phase 1 and two Phase 2 Clinical Trials.
- Phase 1 completed with positive results.
- Phase 2a completed with positive results
 - Phase 2b to commence in March 2024.
- All three clinical trials fully funded by MindBio.
- Highly experienced board appointed to MindBio.
- MindBio listed on the Canadian Securities Exchange in 2023. Blackhawk shareholders received 78,252,003 shares in MindBio spinout.



Sienna Mining


Extensive Landholding

8 Prospecting Licences granted and 7 under application in highly prospective Ruvuma region of southern Tanzania.

Mkuju Project covers over 3,310km² of which 1,388km² has been granted, remainder in application.

Properties surround:

- The world class 125Mlbs U₃O₈ Nyota Uranium Deposit owned and being developed by Rosatom
- Likuyu North uranium deposit 4.6Mlbs @ 267ppm U₃O₈
- Prospecting licences are long lived: over six years before converting to a mining licence
- Rosatom's Nyota Uranium Deposit acquired for \$1.2 billion



Sienna Mining

Neighbors to Two World Class U Deposits

- Uranium forms as roll front deposits in Karoo sediments
- Sediments derived from uranium bearing source rocks
- Fluvial delta system forms ideal host to roll front style uranium deposits
- These sediments host the \$1.2B Nyota deposit and the emerging Likuyu North deposit, collectively holding 130M lbs U308
- Sienna holds ground on the same trend as, and sits between, these two deposits in the same sedimentary sequence and adjacent to the Nyota Fault

HB


HARDENBROOK
GROUP



Sienna Mining

- Surface sampling shows high uranium anomalism:
 - Grab samples returned up to 640 ppm U₃O₈
- Over 7 km strike length of anomalous radiometric signature on fault that parallels the fault controlling Nyota
- Ruvuma Prospect is aerially larger than Likuyu North, a resource of 4.6Mlbs @ 267ppm U₃O₈
- Radiometric anomaly at Ruvuma is much more intense than at Likuyu North
- Ruvuma is in the same sedimentary stratigraphy as Likuyu North
- Air core drilling is planned for the current dry season

Image of regional airborne radiometric data




▲ Sienna's Ruvuma Prospect radiometric anomaly on PL 12397 showing surface sampling U₃O₈ in ppm



Sienna Mining

Compelling Geology for Roll Front Style


- Mkuju Project located in the Selous Basin of the Mid-Upper Karoo age sediments
- Area is dissected by NNE faulting
- Fluvial and deltaic sandstones provide porous host rocks
- Shaley interbeds provide the constraining horizons
- Carbonatite, syenite, and granitic intrusives are the source rocks
- PLs cover the highly prospective Mbarangandu Fm, host to Nyota and Likuyu
- Sedimentation cycles identified at Nyota and Likuyu are short-cutting Sienna's learning curve




Sienna Mining

Field Programme to Kick Off

- Ruvuma Prospect less than 9km SE of the Nyota Uranium Project and 22km to the NE of the Likuyu North Uranium Project
- Surface geochemistry returned in excess of 3,500ppm U₃O₈ on north-south airborne radiometric anomaly
- An initial 400m x 500m grid will be drilled to follow-up this anomalous area
- It is planned to drill the 45 holes to a nominal depth of 60m
- The entire area is to be geologically mapped and ground truthed with a gamma ray spectrometer survey
- The target is a Nyota-style uranium deposit with potentially higher grades



Hardenbrook supercharges Blackhawk's Investment Portfolio




Hardenbrook will acccelerate Blackhawk's portfolio with five new companies and a pipeline of new opportunities including a Medical Device company working on a Heart on a Chip, Cancer clinical trials and more....

Life AI Corp – Optimizing Health & Human Performance Using AI

Life AI Corp has 3 core projects in Asthma, Mood & Autism.



Life AI has a robust pipeline of AI projects across several health indications with large unmet need.



Asthmatic AI


Multi Assessment of Risk of Asthma Attacks

The Company will use everyday sensor-based technologies to better predict asthma attacks by collecting real-time data from technologies such as smart watches and smart inhalers. The system can learn from these data using artificial intelligence (AI) to predict risk of future attacks.

The system will be able to learn from data as people with asthma use the technologies. We need to collect data from 500 people with asthma and follow them for 6 months to see how changes in their body relate to the onset of an asthma attack using a smart watch, smart peak flow meter, and smart inhaler. We will then analyse the data to develop a risk prediction model which we will then test in a randomised controlled trial of 100 people to confirm its effectiveness versus standard care.


Predicting Asthma Attacks before they happen!

Asthma Attack Causes




Asthmatic AI Data Collection

Individual-level real time data



Public Health Data

Masses of Public Health Data



Asthmatic AI

Multi Assessment of Risk of Asthma Attacks using wearables and a smart phone

Asthmatic AI has secured the project from the University of Auckland. Nearly 600,000 people have asthma in NZ, and 1 in 4 having one or more asthma attacks each year. The project has already secured \$954,482 in funding.



Human Phase 2 Clinical Trials have been Ethics Approved

- Public health data has been used by our scientists to create AI, ML models to assess risk of asthma attack
- Clinical trials will refine the risk of asthma attack assessment models using individual health data collected in clinical trials
- The models will be used to predict asthma attacks and prevent them before they occur

My Autism AI

25% of Autistic individuals are estimated to remain undetected by the age of 6-7

My Autism AI uses advanced machine learning technologies to enable early, accessible, affordable, and accurate detection of autism in individuals by mining intelligence from historical autism data.



My Autism AI


My Autism AI – Accurate, Early Autism Detection

The mean age of diagnosis of autism is 6-7 years.

- usually 2-3 years after families /caregiver express concerns.
- three years later than the optimal age for delivering early language and other key supports.

Our Solution

A multimodal, ensemble Deep Learning based system for autodetection of autism spectrum



A multimodal, ensemble Deep Learning based system for autodetection of autism spectrum

My Autism AI



My Autism AI

A Diagnostic Tool for Early Autism Detection

- The first module of My Autism AI has been operational since 2018
- Data from more than 10,000 participants across the globe, mainly in the US has been collected
- The next stage of development is the creation and testing of a Diagnostic Tool for use and validation by Autism clinical experts



MOODAI

Mood AI is developing a Prediction Model for Diagnosing and Treating Mental Health Conditions


- AI is used to obtain a patient's unique biophysical insights from wearables and accurately predict negative mood states before they occur.
- A Mobile App will be used to Intervene and interrupt negative thought patterns using clinically proven strategies.
- AI is used to detect subtle changes in physiology from wearables and intervene before the onset of anxiety, depression and other negative mood states.

Mood AI – Artificial Intelligence powered mental health treatment

Personalized machine learning algorithms scan a patient's biometric data from wearables constantly learning about the patient.

AI learns when to intervene and what types of interventions are useful on an individual basis.

Using wearables & a smartphone to detect, predict & prevent depression & anxiety before it occurs





MOODAI

Human Phase 2 Clinical Trials have received Ethics Approval

- Mood AI Team has significant experience in neuropsychopharmacology, clinical trial development and participant recruitment.
- Mood AI App will be used in clinical trials to collect individual biophysical markers such as heart rate, heart rate variability, sleep quality and activity.
- Clinical Trials will provide clinical validation of Mood AI models and strengthen the validity of personalized interventions delivered by the AI for use in a clinical setting.

Contact Us

Justin Hanka

justin@hardenbrook.group